These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16703305)

  • 1. Serious doubts on safety and efficacy of CCR5 antagonists : CCR5 antagonists teeter on a knife-edge.
    Horster S; Goebel FD
    Infection; 2006 Apr; 34(2):110-3. PubMed ID: 16703305
    [No Abstract]   [Full Text] [Related]  

  • 2. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature.
    Emmelkamp JM; Rockstroh JK
    Eur J Med Res; 2007 Oct; 12(9):409-17. PubMed ID: 17933722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Secondary effects of treatment with maraviroc and other CCR5 antagonists. Potential impact of the CCR5 blocker].
    Arribas López JR
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():23-7. PubMed ID: 19133218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1.
    Bredeek UF; Harbour MJ
    Eur J Med Res; 2007 Oct; 12(9):427-34. PubMed ID: 17933724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two new drugs for HIV infection.
    Med Lett Drugs Ther; 2008 Jan; 50(1277):2-4. PubMed ID: 18197163
    [No Abstract]   [Full Text] [Related]  

  • 6. [New antiretroviral drug classes in HIV therapy].
    Lehmann C; Meuer K; Kümmerle T; Fätkenheuer G
    MMW Fortschr Med; 2009 Apr; 151(18):64-6. PubMed ID: 19769081
    [No Abstract]   [Full Text] [Related]  

  • 7. [CCR5 antagonists: a new class of antiretrovirals].
    de la Tribonnière X; Yazdanpanah Y; Reynes J
    Med Mal Infect; 2008 Mar; 38 Suppl 1():S1-6. PubMed ID: 18455055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA notifications. Maraviroc approved as a CCR5 co-receptor antagonist.
    AIDS Alert; 2007 Sep; 22(9):103. PubMed ID: 18411462
    [No Abstract]   [Full Text] [Related]  

  • 9. Something new under the sun. Maraviroc poised for approval.
    Huff B
    GMHC Treat Issues; 2006; 20(8-12):1-4. PubMed ID: 17569160
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of HIV infection with the CCR5 antagonist maraviroc.
    Kromdijk W; Huitema AD; Mulder JW
    Expert Opin Pharmacother; 2010 May; 11(7):1215-23. PubMed ID: 20402558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maraviroc: a new CCR5 antagonist.
    Sayana S; Khanlou H
    Expert Rev Anti Infect Ther; 2009 Feb; 7(1):9-19. PubMed ID: 19622053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCR5 antagonists in the treatment of treatment-experienced patients infected with CCR5 tropic HIV-1.
    Lorenzen T; Stoehr A; Walther I; Plettenberg A
    Eur J Med Res; 2007 Oct; 12(9):419-25. PubMed ID: 17933723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pretreated HIV patients profit from Maraviroc. Oral HIV fusion inhibitor opens new therapy chances].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():52-3. PubMed ID: 19024918
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug safety evaluation of maraviroc for the treatment of HIV infection.
    Wasmuth JC; Rockstroh JK; Hardy WD
    Expert Opin Drug Saf; 2012 Jan; 11(1):161-74. PubMed ID: 22118500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent use of statins does not influence efficacy of maraviroc in Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients 1 and 2 trials.
    Moyle G; Rajicic N; Goodrich J; Mayer H; Valdez H
    AIDS; 2009 Jul; 23(12):1613. PubMed ID: 19622911
    [No Abstract]   [Full Text] [Related]  

  • 16. Maraviroc: integration of a new antiretroviral drug class into clinical practice.
    Vandekerckhove L; Verhofstede C; Vogelaers D
    J Antimicrob Chemother; 2008 Jun; 61(6):1187-90. PubMed ID: 18400807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCR5 antagonists in the treatment of HIV-infected persons: is their cancer risk increased, decreased, or unchanged.
    McNiff T; Dezube BJ
    AIDS Read; 2009; 19(6):218-22, 224. PubMed ID: 19642239
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel CCR5 antagonists for the treatment of HIV infection: a review of compounds patented in 2006 - 2008.
    Yang H; Rotstein DM
    Expert Opin Ther Pat; 2010 Mar; 20(3):325-54. PubMed ID: 20180619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When and how to use maraviroc in HIV-infected patients.
    Soriano V; Perno CF; Kaiser R; Calvez V; Gatell JM; di Perri G; Pillay D; Rockstroh J; Geretti AM
    AIDS; 2009 Nov; 23(18):2377-85. PubMed ID: 19834318
    [No Abstract]   [Full Text] [Related]  

  • 20. Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study.
    Currier J; Lazzarin A; Sloan L; Clumeck N; Slims J; McCarty D; Steel H; Kleim JP; Bonny T; Millard J;
    Antivir Ther; 2008; 13(2):297-306. PubMed ID: 18505181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.